Rankings
▼
Calendar
RAPP Q1 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
RAPP
Rapport Therapeutics, Inc. Common Stock
$1B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$152,000
Operating Income
-$17M
Net Income
-$23M
EPS (Diluted)
$-0.12
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$19M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$206M
Total Liabilities
$246M
Stockholders' Equity
-$40M
Cash & Equivalents
$74M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$152,000
-$15,000
-913.3%
Operating Income
-$17M
-$5M
-229.3%
Net Income
-$23M
-$6M
-268.8%
← FY 2024
All Quarters
Q2 2024 →